<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Seferović, Petar M.</style></author><author><style face="normal" font="default" size="100%">Pieske, Burkert</style></author><author><style face="normal" font="default" size="100%">Fdez-Avilés, Francisco</style></author><author><style face="normal" font="default" size="100%">Thompson, Randall C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Heart Failure: Updates in Diagnosis and Treatment</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-27 10:52:03</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-30</style></pages><abstract><style  face="normal" font="default" size="100%">New imaging techniques and biomarkers are poised to improve the diagnosis of heart failure. The treatment of heart failure with preserved or reduced ejection fraction remains challenging. New drug treatments under investigation are natriuretic peptides, relaxin, ivabradine, spironolactone, and neprilysin. Stem cell therapy in heart failure is an active area of research.</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>